CNTX

Context Therapeutics (CNTX)

Context Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CNTX

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/17	05 : 01	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:CNTX	Context Therapeutics Inc
2024/05/11	05 : 00	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:CNTX	Context Therapeutics Inc
2024/05/09	05 : 06	GlobeNewswire Inc.	Context Therapeutics Reports First Quarter 2024 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
2024/05/09	05 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CNTX	Context Therapeutics Inc
2024/05/02	20 : 31	GlobeNewswire Inc.	Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76	NASDAQ:CNTX	Context Therapeutics Inc
2024/05/02	20 : 30	GlobeNewswire Inc.	Context Therapeutics Announces $100 Million Private Placement	NASDAQ:CNTX	Context Therapeutics Inc
2024/04/01	20 : 30	GlobeNewswire Inc.	Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers	NASDAQ:CNTX	Context Therapeutics Inc
2024/03/21	20 : 43	GlobeNewswire Inc.	Context Therapeutics Reports Full Year 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
2024/03/06	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CNTX	Context Therapeutics Inc
2024/02/08	06 : 24	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CNTX	Context Therapeutics Inc
2023/11/10	06 : 15	GlobeNewswire Inc.	Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
2023/11/10	06 : 04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CNTX	Context Therapeutics Inc
2023/10/31	22 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CNTX	Context Therapeutics Inc
2023/10/31	22 : 00	GlobeNewswire Inc.	Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76	NASDAQ:CNTX	Context Therapeutics Inc
2023/09/27	22 : 00	GlobeNewswire Inc.	Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	NASDAQ:CNTX	Context Therapeutics Inc
2023/08/10	05 : 10	GlobeNewswire Inc.	Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
2023/08/10	05 : 04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CNTX	Context Therapeutics Inc
2023/08/07	21 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CNTX	Context Therapeutics Inc
2023/08/01	20 : 30	GlobeNewswire Inc.	Context Therapeutics to Participate in Two August 2023 Investor Conferences	NASDAQ:CNTX	Context Therapeutics Inc
2023/06/20	21 : 36	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CNTX	Context Therapeutics Inc
2023/06/01	05 : 53	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CNTX	Context Therapeutics Inc
2023/05/11	05 : 39	GlobeNewswire Inc.	Context Therapeutics Reports First Quarter 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
2023/04/03	20 : 30	GlobeNewswire Inc.	Context Therapeutics to Participate in Two April 2023 Investor Conferences	NASDAQ:CNTX	Context Therapeutics Inc
2023/03/28	05 : 04	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:CNTX	Context Therapeutics Inc
2023/03/23	06 : 10	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CNTX	Context Therapeutics Inc
2023/03/23	06 : 08	GlobeNewswire Inc.	Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates	NASDAQ:CNTX	Context Therapeutics Inc
2023/03/15	20 : 30	GlobeNewswire Inc.	Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023	NASDAQ:CNTX	Context Therapeutics Inc
2023/02/15	07 : 26	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CNTX	Context Therapeutics Inc
2023/02/15	07 : 26	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CNTX	Context Therapeutics Inc
2023/02/15	07 : 25	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CNTX	Context Therapeutics Inc